ARQT

Arcutis Biotherapeutics, Inc. NASDAQ Listed Jan 31, 2020

Healthcare ·Biotechnology ·US · arcutis.com

$24.17

After hrs $23.02 -4.76%

Mkt Cap $3.0B

52w Low $12.42 60.7% of range 52w High $31.77

50d MA $23.76 200d MA $22.93

P/E (TTM) -179.6x

EV/EBITDA 1475.1x

P/B 15.7x

Debt/Equity 0.0x

ROE -8.5%

P/FCF -585.5x

RSI (14) —

ATR (14) —

Beta 1.77

50d MA $23.76

200d MA $22.93

Avg Volume 1.3M

About

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 25, 2026	AMC	0.03	0.13	+333.3%	27.01	+2.5%	+5.8%	-0.1%	-8.3%	-12.6%	-10.7%	—
Oct 28, 2025	AMC	-0.10	0.06	+160.0%	24.95	+3.6%	+1.4%	-0.1%	+1.4%	-0.8%	-3.8%	—
Aug 6, 2025	AMC	-0.18	-0.13	+27.8%	15.36	+5.9%	-8.1%	-3.8%	-7.6%	-4.0%	+1.8%	—
May 6, 2025	AMC	-0.21	-0.20	+4.8%	14.32	-0.6%	-4.3%	-5.6%	-5.5%	+0.5%	-3.5%	—
Feb 25, 2025	AMC	-0.28	-0.09	+67.9%	12.20	+13.5%	+8.4%	+4.9%	+12.2%	+5.2%	+9.8%	—
Nov 6, 2024	AMC	-0.42	-0.33	+21.4%	9.66	+6.6%	+7.7%	+12.0%	+12.2%	+6.1%	+8.4%	—
Aug 14, 2024	AMC	-0.48	-0.42	+12.5%	9.58	-4.0%	-11.3%	-11.4%	-9.7%	-12.1%	-12.9%	—
May 14, 2024	AMC	-0.60	-0.32	+46.7%	8.13	+15.9%	+13.7%	+12.2%	+13.2%	+15.0%	+16.6%	—
Feb 27, 2024	AMC	-0.65	-0.72	-10.8%	10.63	+0.3%	-2.1%	-3.3%	+10.7%	+3.0%	+2.5%	—
Nov 3, 2023	AMC	-0.90	-0.73	+18.9%	2.44	+2.5%	-4.1%	-3.7%	-9.8%	-18.0%	-21.9%	—
Aug 8, 2023	AMC	-1.22	-1.16	+4.9%	9.83	+5.1%	-4.5%	-5.6%	-8.9%	-11.6%	-13.8%	—
May 9, 2023	AMC	-1.30	-1.31	-0.8%	14.82	-0.7%	-18.8%	-26.9%	-32.0%	-30.5%	-32.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 2	Mizuho	Maintains	Outperform → Outperform	—	$26.97	$25.94	-3.8%	-8.2%	-12.5%	-10.6%	-11.1%	-11.0%
Feb 27	Guggenheim	Maintains	Buy → Buy	—	$28.57	$27.95	-2.2%	-5.6%	-13.3%	-17.4%	-15.6%	-16.1%
Feb 26	TD Cowen	Maintains	Buy → Buy	—	$27.01	$27.69	+2.5%	+5.8%	-0.1%	-8.3%	-12.6%	-10.7%
Feb 26	Needham	Maintains	Buy → Buy	—	$27.01	$27.69	+2.5%	+5.8%	-0.1%	-8.3%	-12.6%	-10.7%
Feb 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$27.01	$27.69	+2.5%	+5.8%	-0.1%	-8.3%	-12.6%	-10.7%
Jan 26	Needham	Maintains	Buy → Buy	—	$26.20	$25.80	-1.5%	+0.5%	+0.5%	-2.9%	-1.8%	-3.2%
Nov 28	Mizuho	Maintains	Outperform → Outperform	—	$30.96	$31.27	+1.0%	-1.0%	-1.9%	-4.9%	-3.2%	+0.6%
Oct 30	Goldman Sachs	Maintains	Neutral → Neutral	—	$25.29	$25.89	+2.4%	-1.5%	+0.1%	-2.1%	-5.1%	-3.6%
Oct 28	Needham	Maintains	Buy → Buy	—	$19.64	$22.50	+14.6%	+27.0%	+28.8%	+26.9%	+28.9%	+26.1%
Aug 7	Needham	Maintains	Buy → Buy	—	$15.36	$16.27	+5.9%	-8.1%	-3.8%	-7.6%	-4.0%	+1.8%
May 23	Needham	Maintains	Buy → Buy	—	$13.66	$13.49	-1.2%	+2.3%	+3.5%	-0.6%	+0.1%	-4.5%
Apr 9	Needham	Maintains	Buy → Buy	—	$13.29	$12.87	-3.2%	+9.6%	+1.1%	-5.3%	-2.6%	-0.8%
Apr 3	Guggenheim	Maintains	Buy → Buy	—	$16.60	$15.95	-3.9%	-2.7%	-11.3%	-13.9%	-19.9%	-12.2%
Apr 3	Needham	Maintains	Buy → Buy	—	$16.60	$15.95	-3.9%	-2.7%	-11.3%	-13.9%	-19.9%	-12.2%
Apr 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.60	$15.95	-3.9%	-2.7%	-11.3%	-13.9%	-19.9%	-12.2%
Mar 11	Jefferies	Maintains	Buy → Buy	—	$14.38	$14.39	+0.1%	+7.7%	+5.4%	+3.0%	+1.7%	+14.2%
Feb 27	Goldman Sachs	Maintains	Neutral → Neutral	—	$13.22	$13.24	+0.2%	-3.2%	+3.6%	-3.0%	+1.4%	+11.8%
Feb 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.20	$13.85	+13.5%	+8.4%	+4.9%	+12.2%	+5.2%	+9.8%
Feb 26	Needham	Maintains	Buy → Buy	—	$12.20	$13.85	+13.5%	+8.4%	+4.9%	+12.2%	+5.2%	+9.8%
Feb 26	Mizuho	Maintains	Outperform → Outperform	—	$12.20	$13.85	+13.5%	+8.4%	+4.9%	+12.2%	+5.2%	+9.8%
Feb 24	Guggenheim	Maintains	Buy → Buy	—	$13.02	$12.96	-0.5%	-4.8%	-6.3%	+1.5%	-1.7%	+5.1%
Feb 10	Guggenheim	Maintains	Buy → Buy	—	$11.61	$11.75	+1.2%	-0.2%	-1.8%	+13.8%	+6.0%	+10.1%
Jan 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.81	$14.99	+8.5%	-1.3%	-3.8%	+0.8%	-0.4%	-8.2%
Jan 7	Mizuho	Maintains	Outperform → Outperform	—	$14.71	$15.13	+2.9%	+7.1%	+3.8%	-6.1%	-7.3%	-9.7%
Dec 17	Needham	Maintains	Buy → Buy	—	$13.57	$13.45	-0.9%	+9.5%	-1.3%	+4.0%	+10.5%	+10.3%
Nov 7	Needham	Maintains	Buy → Buy	—	$9.66	$10.30	+6.6%	+7.7%	+12.0%	+12.2%	+6.1%	+8.4%
Aug 15	Needham	Maintains	Buy → Buy	—	$9.58	$9.20	-4.0%	-11.3%	-11.4%	-9.7%	-12.1%	-12.9%
Jul 30	Needham	Maintains	Buy → Buy	—	$9.57	$9.68	+1.1%	+0.6%	+5.2%	-0.9%	-3.3%	-4.9%
Jul 10	Needham	Maintains	Buy → Buy	—	$10.02	$10.32	+3.0%	-2.1%	+7.1%	+6.0%	+7.5%	+6.5%
May 15	Needham	Maintains	Buy → Buy	—	$8.13	$9.42	+15.9%	+13.7%	+12.2%	+13.2%	+15.0%	+16.6%
May 15	Mizuho	Maintains	Buy → Buy	—	$8.13	$9.42	+15.9%	+13.7%	+12.2%	+13.2%	+15.0%	+16.6%
Apr 12	Needham	Maintains	Buy → Buy	—	$11.88	$11.77	-0.9%	-14.1%	-15.1%	-15.0%	-13.7%	-20.5%
Feb 28	Mizuho	Maintains	Buy → Buy	—	$10.63	$10.66	+0.3%	-2.1%	-3.3%	+10.7%	+3.0%	+2.5%
Feb 28	Goldman Sachs	Maintains	Neutral → Neutral	—	$10.63	$10.66	+0.3%	-2.1%	-3.3%	+10.7%	+3.0%	+2.5%
Feb 28	Needham	Maintains	Buy → Buy	—	$10.63	$10.66	+0.3%	-2.1%	-3.3%	+10.7%	+3.0%	+2.5%
Feb 23	Mizuho	Maintains	Buy → Buy	—	$9.62	$9.88	+2.7%	+0.6%	+0.7%	+10.5%	+8.2%	+6.9%
Jan 3	Mizuho	Upgrade	Neutral → Buy	—	$3.43	$3.67	+7.0%	+14.0%	+17.8%	+8.2%	+18.1%	+18.1%
Jan 2	Mizuho	Upgrade	Neutral → Buy	—	$3.23	$3.17	-1.9%	+6.2%	+21.1%	+25.1%	+14.9%	+25.4%
Nov 13	Morgan Stanley	Maintains	Overweight → Overweight	—	$1.91	$1.87	-1.8%	+10.8%	+14.4%	+9.2%	+2.4%	+7.1%
Nov 8	JonesTrading	Downgrade	Buy → Hold	—	$2.35	$2.37	+0.9%	-6.4%	-14.9%	-18.9%	-10.2%	-7.2%
Nov 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.44	$2.50	+2.5%	-4.1%	-3.7%	-9.8%	-18.0%	-21.9%
Nov 6	Needham	Maintains	Buy → Buy	—	$2.44	$2.50	+2.5%	-4.1%	-3.7%	-9.8%	-18.0%	-21.9%
Oct 27	Mizuho	Downgrade	Buy → Neutral	—	$2.37	$2.40	+1.3%	-1.5%	-3.0%	-5.1%	-4.6%	-6.3%
Oct 13	Goldman Sachs	Downgrade	Buy → Neutral	—	$3.88	$3.53	-9.0%	+0.0%	-3.2%	-0.8%	-16.8%	-21.9%
Sep 25	Mizuho	Maintains	Buy → Buy	—	$5.38	$5.52	+2.6%	+7.4%	+8.4%	+3.7%	+3.0%	-1.3%
Aug 22	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$7.28	$7.27	-0.1%	+3.1%	+3.4%	+3.1%	+6.4%	+10.2%
Aug 10	Needham	Maintains	Buy → Buy	—	$9.39	$9.40	+0.1%	-1.2%	-4.6%	-7.5%	-9.8%	-12.6%
Aug 9	TD Cowen	Maintains	Outperform → Outperform	—	$9.83	$10.33	+5.1%	-4.5%	-5.6%	-8.9%	-11.6%	-13.8%
Jul 18	Needham	Maintains	Buy → Buy	—	$10.98	$10.96	-0.2%	-3.6%	-5.3%	-5.6%	-4.5%	-6.2%
Jun 28	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$8.47	$8.50	+0.4%	+1.8%	-1.7%	+12.5%	+3.3%	+9.7%

Insider Trades

Date	Insider	Title	Type	Shares	Price	Value	Owned After	D1%	D5%
May 1, 2026	Welgus Howard G.Dir	—	Sell	7,144	$22.99	$164K	32,600	+3.20%	—

Recent Filings

8-K · 5.02 !!! Very High

MBX Biosciences, Inc. -- 8-K 5.02: Executive Change

MBX Biosciences replaced CFO Richard Bartram with interim CFO John Smither, effective March 16, 2026, signaling potential leadership transition during a critical period for the company.

Feb 27

8-K

Arcutis Biotherapeutics, Inc. -- 8-K Filing

Arcutis Biotherapeutics achieved over 90% year-over-year net product revenue growth in 2025, driven by strong ZORYVE demand and successful multi-product launches in its immuno-dermatology focus area.

Feb 25

Data updated apr 24, 2026 7:00pm · Source: massive.com